Contrast Media Market

Contrast Media Market by Type (Iodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, CT, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) & Region - Global Forecast to 2029

Report Code: MD 3577 Feb, 2024, by marketsandmarkets.com

The global contrast media market in terms of revenue was estimated to be worth $6.3 Billion in 2023 and is poised to reach $9.7 Billion by 2029, growing at a CAGR of 7.5% from 2023 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by rising number of hospitals and diagnostic imaging centers, awareness regarding early diagnosis and rising prevalence of chronic conditions. On the other hand, the adverse effects associated with the use of contrast media will restrain the growth of this market to a certain extent.

 

Attractive Opportunities in the Contrast Media Market

Contrast Media Market

To know about the assumptions considered for the study, Request for Free Sample Report

Contrast Media Market

Contrast Media Market Dynamics

DRIVER: Increasing prevalence of chronic medical conditions

Globally, there has been a significant increase in the number of people suffering from cancer. In various countries across the globe, people are adopting a sedentary lifestyle, which is characterized by a high-calorie diet (that is rich in fat, refined carbohydrates, and animal protein) and low physical activity. With such changes in lifestyle, the number of people suffering from cancer is expected to increase.

Over the years, the prevalence of chronic diseases such as cardiovascular disease (CVD) and cancer has increased significantly. Some key statistics in this regard have been mentioned below:

  • According to an article published by the Pan American Health Organization (PAHO), globally, there were 20 million new cancer cases and 10 million cancer deaths. Projections indicate a projected 60% increase in the cancer burden over the next two decades. The anticipated worldwide burden is set to rise to around 30 million new cancer cases by 2040, with the most significant increases expected in low- and middle-income countries.
  • According to estimates from the International Agency for Research on Cancer (IARC), globally, new cancer cases are expected to grow to 27.5 million, and 16.3 million cancer deaths are expected to occur due to the growing population by 2040.
  • According to the JACC Journals’ findings in 2021, elevated systolic blood pressure continues to stand as the primary modifiable risk factor worldwide for premature cardiovascular deaths. It contributed to approximately 10.8 million cardiovascular deaths and a total of 11.3 million deaths globally in 2021.
  • According to the American Heart Association (AHA), by 2030, 40.5% of the US population is projected to have some form of CVD.
  • According to the Centers for Disease Control and Prevention (CDC), in 2021, heart disease maintained its position as the foremost cause of mortality in the US. Approximately 695,000 individuals in the United States succumbed to heart disease in that year, representing 1 in every 5 deaths.

RESTRAINT: Side effects associated with the use of contrast media

Contrast media are generally considered safe to use for various diagnostic procedures, such as MRI and CT scans. However, their use might be limited in certain patients due to side effects and allergic reactions, which can hinder the growth of the market to a certain extent. Their adverse reactions range from mild to severe; however, severe reactions are very uncommon, and severe allergic responses to contrast materials are rare. For instance, as per an article published by the NIH, the incidence of immediate reactions to nonionic contrast media ranges from 0.01–0.04% (severe) to 3% (mild). Nonionic agents are associated with a decreased risk of adverse reactions.

OPPORTUNITY: Increasing research on contrast media

Rising R&D into novel contrast media, as well as the development of newer applications of contrast media, provide immense opportunities for market players. Companies, research institutes, and universities across the globe are undertaking projects to develop novel contrast media and expand their applications. In October 2022, researcher Stefan Glöggler devised an effective contrast agent technique for MRI, potentially enabling the differentiation between tumors and healthy tissue based on their metabolic activity. The ForTra GmbH für Forschungstransfer of the Else Kröner-Fresenius Foundation (ForTra) and the European Research Council (ERC) are now offering financial support to advance this method for clinical patient trials. Similarly, in 2020, a biochemistry and pharmacology professor, Dr. Gang Han, received USD 25,000 in seed funding from the UMass Technology Development Fund for research on MRI contrast media or gadolinium-based agents with fewer adverse effects.

CHALLENGE: Dearth of trained professionals

A high degree of technical skill and expertise is needed to conduct advanced and sophisticated diagnostic imaging procedures. As per data from the US Bureau of Labor Statistics, radiology technicians are anticipated to witness an employment growth of nearly 6% during between 2022 and 2032. While this growth is significant, the shortage of specialists and trained radiologists will challenge market growth.

  • According to the Association of Radiologists of Nigeria, the number of radiologists in Nigeria is about 400 for 200 million people, which is grossly inadequate to meet the requirements of the people in the country.
  • According to an article in October 2023, India is facing a concerning healthcare challenge with an inadequate ratio of radiologists to population. With only around 20,000 radiologists catering to a population exceeding 1.4 billion, the country has a striking ratio of one radiologist for every 1,00,000 individuals, significantly below global healthcare standards.
  • According to an NIH article published in September 2023, Malaysia faces a pressing need for additional radiologists compared to more developed nations. With just 870 registered radiologists serving a population of 33.57 million, the ratio stands at 3.9 per 100,000 individuals.
  • The World Health Organization (WHO) highlights a global challenge, revealing that over two-thirds of the world’s population lacks access to radiology. Developing nations, particularly in Africa, face a critical situation where 14 countries lack access to a single radiologist. Even in developed countries like the UK and Australia, there exists a notable disparity, with major cities having more radiologists compared to rural areas on a per capita basis.

Contrast Media Industry Ecosystem/Market Map

Contrast Media Market Ecosystem

Radiology segment accounted for the largest share of the contrast media industry in 2022, by application.

Based on application, the contrast media market is segmented into radiology, interventional radiology, and interventional cardiology. Radiology accounted for the market’s largest share in 2022, by application. Radiology plays a crucial role in the early detection and monitoring of various medical conditions, contributing to the higher demand for radiology procedures. The large share of radiology applications can be attributed to factors such as the rising geriatric population, increasing prevalence of chronic diseases, and demand for minimally invasive procedures, among others.

Intravascular route segment accounted for the largest share in the contrast media industry in 2022, by route of administration.

On the basis of route of administration, the global contrast media market is categorized into intravascular route, oral route, rectal route, and other routes of administration. In 2022, the intravascular route segment held the largest share in the market, by route of administration. The growth of the segment can be attributed to the fact that most of the contrast media are available in the form of injectable and help in limiting the time needed to administer as compared to a powdered one.

Hospitals, Clinics, and Ambulatory Surgical Centers segment accounted for the largest share in the contrast media industry in 2022, by end user.

Based on end user, the contrast media market is segmented into hospitals, clinics, and ambulatory surgical centers and diagnostic imaging centers. In 2022, the hospitals, clinics, and ambulatory surgical centers segment accounted for the largest share of the global market. Hospitals usually invest more and maintain a broad range of advanced imaging equipment, such as CT scanners, MRI machines, and interventional radiology suites, hence accelerating the demand for contrast media.

North America accounted for the largest share of the contrast media industry in 2022.

The contrast media market is segmented into four major regions: North America, Europe, the Asia Pacific, and the Rest of the World. In 2022, North America emerged as the leading contributor, accounting for the largest share of the market. With the presence of major players in the region, the region has witnessed an increase in the number of product approvals. These companies based in North America have expertise, resources, and well-established sales networks, contributing to the region’s market dominance.

Contrast Media Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in contrast media market are GE Healthcare (US), Bracco Imaging SpA (Italy), Bayer AG (Germany), Guerbet (France), and Lantheus Medical Imaging, Inc. (US). These players’ market leadership is due to their comprehensive product portfolios and expansive global footprint. These dominant market players have several advantages, including strong research and development budgets, strong marketing and distribution networks, and well-established brand recognition.

Scope of the Contrast Media Industry

Report Metric

Details

Market Revenue in 2023

$6.3 Billion

Projected Revenue by 2029

$9.7 Billion

Revenue Rate

Poised to Grow at a CAGR of 7.5%

Market Driver

Increasing prevalence of chronic medical conditions

Market Opportunity

Increasing research on contrast media

This research report categorizes the Contrast Media Market to forecast revenue and analyze trends in each of the following submarkets:

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

By Type

  • Iodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media
  • Barium-based Contrast Media

By Form

  • Liquid
  • Powder
  • Other Forms

By Modality

  • X-ray
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Ultrasound

By Route of Administration

  • Intravascular Route
  • Oral Route
  • Rectal Route
  • Other Routes of Administration

By Indication Split

  • Cardiovascular Diseases
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders

By Application

  • Radiology
  • Interventional Radiology
  • Interventional Cardiology

By End User

  • Hospital, Clinics, and Ambulatory Surgical Centers
  • Diagnostic Imaging Centers

Recent Developments of Contrast Media Industry:

  • In October 2023, The European Commission granted Guerbet marketing authorization (MA) for Elucirem (Gadopiclenol) following the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
  • In April 2023, GE HealthCare expanded its contrast media portfolio by introducing Pixxoscan (gadobutrol), a macrocyclic, non-ionic magnetic resonance imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan underwent regulatory review via a decentralized procedure (DCP), securing marketing authorization in Austria.
  • In September 2022, The company received FDA approval for the VUEWAY Gadopiclenol contrast media injection for use in adult and pediatric patients aged two years and older during magnetic resonance imaging (MRI) scans.
  • In December 2021, Bracco Diagnostics entered into a collaboration agreement with Guerbet for the production and research related to Gadopiclenol, a high-relaxivity macrocyclic contrast agent.
  • In March 2021, Guerbet and Bracco Imaging entered into a global strategic collaboration agreement for Gadopiclenol. The companies will collaborate on manufacturing, research, and development for potential future indications. Upon regulatory approval, they will independently commercialize Gadopiclenol, an investigational GBCA, under separate brands.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 23)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION
           1.3.2 REGIONAL SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 MARKET STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 5 REVENUE SHARE ANALYSIS
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 7 CONTRAST MEDIA INDUSTRY: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
           2.5.1 MARKET ASSUMPTIONS
           2.5.2 GROWTH RATE ASSUMPTIONS
    2.6 RESEARCH LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT ANALYSIS
    2.8 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 41)
    FIGURE 9 CONTRAST MEDIA MARKET, BY TYPE, 2023 VS. 2029 (USD BILLION)
    FIGURE 10 CONTRAST MEDIA INDUSTRY, BY FORM, 2023 VS. 2029 (USD BILLION)
    FIGURE 11 MARKET, BY MODALITY, 2023 VS. 2029 (USD BILLION)
    FIGURE 12 MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2029 (USD BILLION)
    FIGURE 13 MARKET, BY INDICATION, 2023 VS. 2029 (USD BILLION)
    FIGURE 14 MARKET, BY APPLICATION, 2023 VS. 2029 (USD BILLION)
    FIGURE 15 MARKET, BY END USER, 2023 VS. 2029 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 CONTRAST MEDIA MARKET OVERVIEW 
          FIGURE 17 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
    4.2 NORTH AMERICA: CONTRAST MEDIA INDUSTRY, BY END USER & COUNTRY (2022) 
          FIGURE 18 HOSPITALS, CLINICS, & AMBULATORY SURGERY CENTERS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MARKET: REGIONAL MIX 
          FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
              4.4 MARKET: DEVELOPED VS. DEVELOPING MARKETS 
                     FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA AND INDIA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 CONTRAST MEDIA MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of chronic diseases
                                TABLE 2 CANCER INCIDENCE, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                                TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2020 VS. 2030 VS. 2040
                    5.2.1.2 Growing number of approvals of contrast media
                    5.2.1.3 Rising volume of CT and MRI examinations performed
                                TABLE 4 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019–2021
                                TABLE 5 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019–2021
                    5.2.1.4 Growing number of diagnostic centers and hospitals
                    5.2.1.5 Availability of reimbursement
                    5.2.1.6 Increasing demand for early disease diagnosis
                    5.2.1.7 Increasing funding by public-private organizations
                                TABLE 6 LIST OF BENEFICIARY HOSPITALS OF NHS WALES
           5.2.2 RESTRAINTS
                    5.2.2.1 Side-effects and risks of allergic reactions associated with contrast media
                                TABLE 7 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Generic contrast media
                    5.2.3.2 Increasing research on contrast media
                                TABLE 8 INDICATIVE LIST OF RESEARCH STUDIES
                    5.2.3.3 Growth opportunities in emerging economies
                    5.2.3.4 Increasing demand for minimally invasive imaging procedures
           5.2.4 CHALLENGES
                    5.2.4.1 Preference for alternative modalities of imaging that do not require contrast media
                    5.2.4.2 Restriction of linear gadolinium-based contrast media and product recalls
                    5.2.4.3 Dearth of trained professionals
                                TABLE 9 US: METROPOLITAN AREAS WITH HIGH EMPLOYMENT LEVELS FOR RADIOLOGY TECHNOLOGISTS AND TECHNICIANS, 2022
                    5.2.4.4 Shortage of contrast media
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 23 VALUE CHAIN ANALYSIS: CONTRAST MEDIA INDUSTRY
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 SUPPLY CHAIN ANALYSIS: MARKET
    5.5 TECHNOLOGY ANALYSIS 
    5.6 PORTER’S FIVE FORCES ANALYSIS 
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 INTENSITY OF COMPETITIVE RIVALRY
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 BARGAINING POWER OF SUPPLIERS
           5.6.5 THREAT OF SUBSTITUTES
    5.7 REGULATORY LANDSCAPE 
          TABLE 10 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING MARKET
           5.7.1 EU REGULATIONS
           5.7.2 FDA REGULATIONS
           5.7.3 JPMA REGULATIONS
    5.8 PATENT ANALYSIS 
          FIGURE 25 PATENT ANALYSIS: IODINATED CONTRAST MEDIA
          FIGURE 26 PATENT ANALYSIS: GADOLINIUM-BASED CONTRAST MEDIA
    5.9 KEY CONFERENCES & EVENTS IN 2024–2025 
          TABLE 11 LIST OF CONFERENCES & EVENTS IN MARKET
    5.10 PRICING ANALYSIS 
           TABLE 12 AVERAGE SELLING PRICE OF CONTRAST MEDIA
    5.11 TRADE ANALYSIS 
           TABLE 13 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018–2022 (USD MILLION)
           TABLE 14 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018–2022 (USD MILLION)
    5.12 ECOSYSTEM ANALYSIS 
           FIGURE 27 ECOSYSTEM ANALYSIS: MARKET
           TABLE 15 ROLE IN ECOSYSTEM
           FIGURE 28 KEY PLAYERS OPERATING IN MARKET
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
                     TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 30 KEY BUYING CRITERIA FOR TOP END USERS
                     TABLE 17 KEY BUYING CRITERIA FOR END USERS
 
6 CONTRAST MEDIA MARKET, BY TYPE (Page No. - 80)
    6.1 INTRODUCTION 
          TABLE 18 CONTRAST MEDIA INDUSTRY, BY TYPE, 2021–2029 (USD MILLION)
    6.2 IODINATED CONTRAST MEDIA 
           6.2.1 HIGH DEMAND FOR IODINATED CONTRAST MEDIA DUE TO HIGHER DOSAGE REQUIRED IN CT SCANS—KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 19 MARKET, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 20 MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
    6.3 GADOLINIUM-BASED CONTRAST MEDIA 
           6.3.1 SUSPICION REGARDING SAFETY PROFILE TO CHALLENGE MARKET GROWTH
                    TABLE 21 MARKET, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 22 MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
    6.4 MICROBUBBLE CONTRAST MEDIA 
           6.4.1 EXTREMELY POPULAR AMONG PHYSICIANS WORLDWIDE
                    TABLE 23 MARKET, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 24 MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
    6.5 BARIUM-BASED CONTRAST MEDIA 
           6.5.1 ADVERSE EFFECTS ASSOCIATED WITH USE TO NEGATIVELY IMPACT MARKET
                    TABLE 25 MARKET, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 26 MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
 
7 CONTRAST MEDIA MARKET, BY FORM (Page No. - 90)
    7.1 INTRODUCTION 
          TABLE 27 CONTRAST MEDIA INDUSTRY, BY FORM, 2021–2029 (USD MILLION)
    7.2 LIQUID CONTRAST MEDIA
           7.2.1 INCREASING ADOPTION OF EASY-TO-USE LIQUID FORM OF CONTRAST MEDIA ACROSS HOSPITALS AND DIAGNOSTIC CENTERS TO DRIVE MARKET
                    TABLE 28 MARKET, BY REGION, 2021–2029 (USD MILLION)
    7.3 POWDER CONTRAST MEDIA 
           7.3.1 EASE OF HANDLING, STORAGE, AND TRANSPORTATION TO FAVOR ADOPTION
                    TABLE 29 MARKET, BY REGION, 2021–2029 (USD MILLION)
    7.4 OTHER FORMS 
          TABLE 30 MARKET FOR OTHER FORMS, BY REGION, 2021–2029 (USD MILLION)
 
8 CONTRAST MEDIA MARKET, BY MODALITY (Page No. - 95)
    8.1 INTRODUCTION 
          TABLE 31 NUMBER OF PROCEDURES PERFORMED, BY MODALITY, 2017–2020
          TABLE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2021–2029 (MILLION LITERS)
          TABLE 33 CONTRAST MEDIA INDUSTRY, BY MODALITY, 2021–2029 (USD MILLION)
    8.2 X-RAY 
           8.2.1 PRODUCTION OF HIGH-QUALITY IMAGES TO DRIVE MARKET
                    TABLE 34 UK: NUMBER OF X-RAY TESTS PERFORMED, 2012–2020
                    TABLE 35 MARKET FOR X-RAY, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 36 MARKET FOR X-RAY, BY COUNTRY, 2021–2029 (USD MILLION)
    8.3 CT 
           8.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET
                    TABLE 37 NUMBER OF CT SCANNERS PER 1,000 INHABITANTS, BY COUNTRY, 2020 VS. 2021
                    TABLE 38 UK: NUMBER OF CT SCANS PERFORMED, 2012–2020
                    TABLE 39 MARKET FOR CT, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 40 MARKET FOR CT, BY COUNTRY, 2021–2029 (USD MILLION)
    8.4 MRI 
           8.4.1 ADVANTAGES OF MRI OVER OTHER IMAGING MODALITIES TO SUPPORT MARKET GROWTH
                    TABLE 41 NUMBER OF MRI UNITS PER 1,000 INHABITANTS, BY COUNTRY, 2019 VS. 2020 VS. 2021
                    TABLE 42 UK: NUMBER OF MRI TESTS PERFORMED, 2012–2020
                    TABLE 43 MARKET FOR MRI, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 44 MARKET FOR MRI, BY COUNTRY, 2021–2029 (USD MILLION)
    8.5 ULTRASOUND 
           8.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY–KEY FACTORS DRIVING MARKET GROWTH
                    TABLE 45 UK: NUMBER OF ULTRASOUND TESTS PERFORMED, 2012–2020
                    TABLE 46 MARKET FOR ULTRASOUND, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 47 MARKET FOR ULTRASOUND, BY COUNTRY, 2021–2029 (USD MILLION)
 
9 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 108)
    9.1 INTRODUCTION 
          TABLE 48 CONTRAST MEDIA INDUSTRY, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
    9.2 INTRAVASCULAR ROUTE 
           9.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTE IN IMAGING MODALITIES TO DRIVE MARKET
                    9.2.1.1 Intravenous (IV) route
                    9.2.1.2 Intra-arterial (IA) route
                                TABLE 49 MARKET FOR INTRAVASCULAR ROUTE, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 50 MARKET FOR INTRAVASCULAR ROUTE, BY COUNTRY, 2021–2029 (USD MILLION)
    9.3 ORAL ROUTE 
           9.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN GIT, LEADING TO PERITONITIS
                    TABLE 51 MARKET FOR ORAL ROUTE, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 52 MARKET FOR ORAL ROUTE, BY COUNTRY, 2021–2029 (USD MILLION)
    9.4 RECTAL ROUTE 
           9.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH
                    TABLE 53 MARKET FOR RECTAL ROUTE, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 54 MARKET FOR RECTAL ROUTE, BY COUNTRY, 2021–2029 (USD MILLION)
    9.5 OTHER ROUTES 
          TABLE 55 MARKET FOR OTHER ROUTES, BY REGION, 2021–2029 (USD MILLION)
          TABLE 56 MARKET FOR OTHER ROUTES, BY COUNTRY, 2021–2029 (USD MILLION)
 
10 CONTRAST MEDIA MARKET, BY INDICATION (Page No. - 117)
     10.1 INTRODUCTION 
             TABLE 57 CONTRAST MEDIA INDUSTRY, BY INDICATION, 2021–2029 (USD MILLION)
     10.2 CARDIOVASCULAR DISEASE 
             10.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET
                        TABLE 58 MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 59 MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2029 (USD MILLION)
     10.3 CANCER 
             10.3.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO HIGH CANCER PREVALENCE IN REGION
                        TABLE 60 CANCER INCIDENCE, BY REGION, 2020 VS. 2035 (MILLION)
                        TABLE 61 MARKET FOR CANCER, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 62 MARKET FOR CANCER, BY COUNTRY, 2021–2029 (USD MILLION)
     10.4 GASTROINTESTINAL DISORDERS 
             10.4.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH
                        TABLE 63 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 64 MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
     10.5 MUSCULOSKELETAL DISORDERS 
             10.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH
                        TABLE 65 MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 66 MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
     10.6 NEUROLOGICAL DISORDERS 
             10.6.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET
                        TABLE 67 MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 68 MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
     10.7 NEPHROLOGICAL DISORDERS 
             10.7.1 RISING PREVALENCE OF ESRD TO DRIVE DEMAND FOR DIAGNOSTIC TOOLS
                        TABLE 69 MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 70 MARKET FOR NEPHROLOGICAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
 
11 CONTRAST MEDIA MARKET, BY APPLICATION (Page No. - 130)
     11.1 INTRODUCTION 
             TABLE 71 CONTRAST MEDIA INDUSTRY, BY APPLICATION, 2021–2029 (USD MILLION)
     11.2 RADIOLOGY 
             11.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET
                        TABLE 72 MARKET FOR RADIOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 73 MARKET FOR RADIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
     11.3 INTERVENTIONAL RADIOLOGY 
             11.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH
                        TABLE 74 MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 75 MARKET FOR INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
     11.4 INTERVENTIONAL CARDIOLOGY 
             11.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET
                        TABLE 76 MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 77 MARKET FOR INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
 
12 CONTRAST MEDIA MARKET, BY END USER (Page No. - 138)
     12.1 INTRODUCTION 
             TABLE 78 CONTRAST MEDIA INDUSTRY, BY END USER, 2021–2029 (USD MILLION)
     12.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 
             12.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET
                        TABLE 79 MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 80 MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2029 (USD MILLION)
     12.3 DIAGNOSTIC IMAGING CENTERS 
             12.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET
                        TABLE 81 MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 82 MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021–2029 (USD MILLION)
 
13 CONTRAST MEDIA MARKET, BY REGION (Page No. - 144)
     13.1 INTRODUCTION 
             TABLE 83 CONTRAST MEDIA INDUSTRY, BY REGION, 2021–2029 (USD MILLION)
     13.2 NORTH AMERICA 
             FIGURE 31 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT
             TABLE 84 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 85 NORTH AMERICA: MARKET, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 86 NORTH AMERICA: MARKET, BY FORM, 2021–2029 (USD MILLION)
             TABLE 87 NORTH AMERICA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
             TABLE 88 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
             TABLE 89 NORTH AMERICA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
             TABLE 90 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
             TABLE 91 NORTH AMERICA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.2.1 US
                        13.2.1.1 Rising incidence of chronic diseases to drive market
                        TABLE 92 US: KEY MACROINDICATORS
                        TABLE 93 US: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 94 US: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                        TABLE 95 US: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                        TABLE 96 US: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                        TABLE 97 US: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                        TABLE 98 US: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.2.2 CANADA
                        13.2.2.1 Increasing investments in improving medical imaging to drive market
                        TABLE 99 CANADA: KEY MACROINDICATORS
                        TABLE 100 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 101 CANADA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                        TABLE 102 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                        TABLE 103 CANADA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                        TABLE 104 CANADA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                        TABLE 105 CANADA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.2.3 RECESSION IMPACT ON NORTH AMERICAN MARKET
     13.3 EUROPE 
             TABLE 106 EUROPE: NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, BY COUNTRY, 2021
             TABLE 107 EUROPE: NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, BY COUNTRY, 2021
             TABLE 108 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 109 EUROPE: MARKET, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 110 EUROPE: MARKET, BY FORM, 2021–2029 (USD MILLION)
             TABLE 111 EUROPE: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
             TABLE 112 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
             TABLE 113 EUROPE: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
             TABLE 114 EUROPE: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
             TABLE 115 EUROPE: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.1 GERMANY
                        13.3.1.1 Presence of well-developed diagnostic imaging infrastructure to support market growth
                                      TABLE 116 GERMANY: KEY MACROINDICATORS
                                      TABLE 117 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 118 GERMANY: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 119 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 120 GERMANY: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 121 GERMANY: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 122 GERMANY: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.2 FRANCE
                        13.3.2.1 Increasing prevalence of cancer to propel market
                                      TABLE 123 FRANCE: KEY MACROINDICATORS
                                      TABLE 124 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 125 FRANCE: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 126 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 127 FRANCE: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 128 FRANCE: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 129 FRANCE: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.3 UK
                        13.3.3.1 Increasing investments in diagnostic imaging to boost market growth
                                      TABLE 130 UK: KEY MACROINDICATORS
                                      TABLE 131 UK: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 132 UK: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 133 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 134 UK: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 135 UK: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 136 UK: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.4 ITALY13.3.4.1 Rising geriatric population to drive demand for diagnostic procedures
                                      TABLE 137 ITALY: KEY MACROINDICATORS
                                      TABLE 138 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 139 ITALY: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 140 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 141 ITALY: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 142 ITALY: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 143 ITALY: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.5 SPAIN
                        13.3.5.1 Shortage of radiologists to restrain market growth
                                      TABLE 144 SPAIN: KEY MACROINDICATORS
                                      TABLE 145 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 146 SPAIN: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 147 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 148 SPAIN: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 149 SPAIN: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 150 SPAIN: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.6 REST OF EUROPE
                        TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2021 VS. 2022
                        TABLE 152 REST OF EUROPE: NUMBER OF MRI AND CT UNITS AND SCANS, BY COUNTRY, 2021
                        TABLE 153 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 154 REST OF EUROPE: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                        TABLE 155 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                        TABLE 156 REST OF EUROPE: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                        TABLE 157 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                        TABLE 158 REST OF EUROPE: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.3.7 RECESSION IMPACT ON EUROPEAN MARKET
     13.4 ASIA PACIFIC 
             FIGURE 32 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT
             TABLE 159 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 160 ASIA PACIFIC: MARKET, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 161 ASIA PACIFIC: MARKET, BY FORM, 2021–2029 (USD MILLION)
             TABLE 162 ASIA PACIFIC: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
             TABLE 163 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
             TABLE 164 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
             TABLE 165 ASIA PACIFIC: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
             TABLE 166 ASIA PACIFIC: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.1 CHINA
                        13.4.1.1 High incidence of cancer and stroke to support market growth
                                      TABLE 167 CHINA: KEY MACROINDICATORS
                                      TABLE 168 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 169 CHINA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 170 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 171 CHINA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 172 CHINA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 173 CHINA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.2 JAPAN
                        13.4.2.1 Strong healthcare sector and high disease incidence to favor market growth
                                      TABLE 174 JAPAN: KEY MACROINDICATORS
                                      TABLE 175 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 176 JAPAN: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 177 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 178 JAPAN: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 179 JAPAN: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 180 JAPAN: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.3 INDIA
                        13.4.3.1 Growing investments in radiology to propel market growth
                                      TABLE 181 INDIA: KEY MACROINDICATORS
                                      TABLE 182 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 183 INDIA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 184 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 185 INDIA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 186 INDIA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 187 INDIA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.4 AUSTRALIA
                        13.4.4.1 Increasing research activities to drive market
                                      TABLE 188 AUSTRALIA: KEY MACROINDICATORS
                                      TABLE 189 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 190 AUSTRALIA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 191 AUSTRALIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 192 AUSTRALIA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 193 AUSTRALIA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 194 AUSTRALIA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.5 REST OF ASIA PACIFIC
                        TABLE 195 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, BY COUNTRY, 2021
                        TABLE 196 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 197 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                        TABLE 198 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                        TABLE 199 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                        TABLE 200 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                        TABLE 201 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.4.6 RECESSION IMPACT ON ASIA PACIFIC MARKET
     13.5 REST OF THE WORLD 
             TABLE 202 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION)
             TABLE 203 REST OF THE WORLD: MARKET, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 204 REST OF THE WORLD: MARKET, BY FORM, 2021–2029 (USD MILLION)
             TABLE 205 REST OF THE WORLD: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
             TABLE 206 REST OF THE WORLD: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
             TABLE 207 REST OF THE WORLD: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
             TABLE 208 REST OF THE WORLD: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
             TABLE 209 REST OF THE WORLD: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.5.1 LATIN AMERICA
                        13.5.1.1 Lack of adequate healthcare infrastructure and poor insurance coverage to limit market growth
                                      TABLE 210 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 211 LATIN AMERICA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 212 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 213 LATIN AMERICA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 214 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 215 LATIN AMERICA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.5.2 MIDDLE EAST & AFRICA
                        13.5.2.1 High burden of chronic diseases to drive market
                                      TABLE 216 ISRAEL: DIAGNOSTIC IMAGING DATA, 2022
                                      TABLE 217 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 218 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 219 MIDDLE EAST & AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 220 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 221 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 222 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.5.3 GCC COUNTRIES
                        13.5.3.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market
                                      TABLE 223 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 224 GCC COUNTRIES: MARKET, BY MODALITY, 2021–2029 (USD MILLION)
                                      TABLE 225 GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION)
                                      TABLE 226 GCC COUNTRIES: MARKET, BY INDICATION, 2021–2029 (USD MILLION)
                                      TABLE 227 GCC COUNTRIES: MARKET, BY APPLICATION, 2021–2029 (USD MILLION
                                      TABLE 228 GCC COUNTRIES: MARKET, BY END USER, 2021–2029 (USD MILLION)
             13.5.4 RECESSION IMPACT ON REST OF THE WORLD MARKET
 
14 COMPETITIVE LANDSCAPE (Page No. - 218)
     14.1 OVERVIEW 
     14.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 229 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET
     14.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA INDUSTRY
     14.4 MARKET SHARE ANALYSIS 
             TABLE 230 CONTRAST MEDIA INDUSTRY: DEGREE OF COMPETITION
             FIGURE 34 CONTRAST MEDIA INDUSTRY SHARE, BY KEY PLAYER (2022)
     14.5 COMPANY EVALUATION MATRIX 
             14.5.1 STARS
             14.5.2 EMERGING LEADERS
             14.5.3 PERVASIVE PLAYERS
             14.5.4 PARTICIPANTS
                        FIGURE 35 CONTRAST MEDIA INDUSTRY: COMPANY EVALUATION MATRIX, 2022
             14.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 231 FOOTPRINT ANALYSIS
                        TABLE 232 TYPE FOOTPRINT
                        TABLE 233 REGIONAL FOOTPRINT
     14.6 STARTUP/SME EVALUATION MATRIX 
             14.6.1 PROGRESSIVE COMPANIES
             14.6.2 RESPONSIVE COMPANIES
             14.6.3 DYNAMIC COMPANIES
             14.6.4 STARTING BLOCKS
                        FIGURE 36 CONTRAST MEDIA INDUSTRY: STARTUP/SME EVALUATION MATRIX, 2022
     14.7 COMPETITIVE BENCHMARKING 
             TABLE 234 CONTRAST MEDIA MARKET: KEY STARTUPS/SMES
     14.8 COMPETITIVE SCENARIO 
             14.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 235 CONTRAST MEDIA INDUSTRY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–DECEMBER 2023
             14.8.2 DEALS
                        TABLE 236 CONTRAST MEDIA INDUSTRY: DEALS, JANUARY 2020–DECEMBER 2023
             14.8.3 OTHER DEVELOPMENTS
                        TABLE 237 CONTRAST MEDIA INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2023
     14.9 BRAND/PRODUCT COMPARISON: CONTRAST MEDIA MARKET 
                        TABLE 238 BRAND/PRODUCT COMPARISON (IODINATED CONTRAST MEDIA)
                        TABLE 239 BRAND/PRODUCT COMPARISON (GADOLINIUM-BASED CONTRAST MEDIA)
 
15 COMPANY PROFILES (Page No. - 232)
(Business overview, Products offered, Recent developments & MnM View)*
     15.1 KEY PLAYERS 
             15.1.1 GE HEALTHCARE
                        TABLE 240 GE HEALTHCARE: BUSINESS OVERVIEW
                        FIGURE 37 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
             15.1.2 BRACCO IMAGING SPA
                        TABLE 241 BRACCO IMAGING SPA: BUSINESS OVERVIEW
             15.1.3 BAYER AG
                        TABLE 242 BAYER AG: BUSINESS OVERVIEW
                        FIGURE 38 BAYER AG: COMPANY SNAPSHOT (2022)
             15.1.4 GUERBET
                        TABLE 243 GUERBET: BUSINESS OVERVIEW
                        FIGURE 39 GUERBET: COMPANY SNAPSHOT (2022)
             15.1.5 LANTHEUS MEDICAL IMAGING
                        TABLE 244 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW
                        FIGURE 40 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2022)
             15.1.6 UNIJULES LIFE SCIENCES LTD.
                        TABLE 245 UNIJULES LIFE SCIENCES LTD.: BUSINESS OVERVIEW
             15.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED
                        TABLE 246 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: BUSINESS OVERVIEW
                        FIGURE 41 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)
             15.1.8 SANOCHEMIA PHARMAZEUTIKA
                        TABLE 247 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW
             15.1.9 TAEJOON PHARM CO., LTD.
                        TABLE 248 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW
             15.1.10 JODAS EXPOIM
                        TABLE 249 JODAS EXPOIM: BUSINESS OVERVIEW
             15.1.11 IMAX DIAGNOSTIC IMAGING LIMITED
                        TABLE 250 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW
             15.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP
                        TABLE 251 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW
             15.1.13 LIVEALTH BIOPHARMA
                        TABLE 252 LIVEALTH BIOPHARMA PVT. LTD.: BUSINESS OVERVIEW
             15.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD.
                        TABLE 253 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     15.2 OTHER PLAYERS 
             15.2.1 UNISPIRE BIOPHARMA PRIVATE LIMITED
             15.2.2 ARCO LIFESCIENCES (I) PVT. LTD.
             15.2.3 STANEX DRUGS & CHEMICALS PVT. LTD.
             15.2.4 REGE IMAGING & CINE FILMS PRIVATE LIMITED
             15.2.5 K DIAM EXIM
             15.2.6 ONKO ILAÇ SAN. VE TIC. A.S.
             15.2.7 FRESENIUS KABI
             15.2.8 BIEM ILAÇ SAN. VE TIC. A.S.
             15.2.9 ADVACARE PHARMA
 
16 APPENDIX (Page No. - 270)
     16.1 DISCUSSION GUIDE 
     16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     16.3 CUSTOMIZATION OPTIONS 
     16.4 RELATED REPORTS 
     16.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as product launches and approvals, expansions, and collaborations of the leading players, the competitive landscape of the contrast media market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the contrast media market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the contrast media market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, and Rest of the World. Approximately 45% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 55%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants:

Contrast Media Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined based on their total revenue. As of 2022, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Bracco Imaging S.p.A (Italy)

Regional Sales Manager

GE Healthcare (US)

VP Marketing

Guerbet (France)

Product Manager

Trivitron Healthcare (India)

Distribution Head

Market Size Estimation

All major product manufacturers offering various contrast media were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value contrast media market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of contrast media market at the regional and country-level
  • Relative adoption pattern of each contrast media market among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country level

Global Contrast Media Market Size: Bottom Up Approach

Contrast Media Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Contrast Media Market Size: Top Down Approach

Contrast Media Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the contrast media industry.

Market Definition

Contrast media are chemical agents used in diagnostic imaging procedures. These formulations help in enhancing the images of body structures and organs when visualized during medical procedures like X-ray, CT, MRI, and ultrasound.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the contrast media market by type, form, modality, route of administration, indication, application, end user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall contrast media market
  • To forecast the size of the contrast media market in four main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific and Rest of the World
  • To profile key players in the contrast media market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product launches and approvals; expansions; and collaborations, of the leading players in the contrast media market
  • To benchmark players within the contrast media market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report

Country Information

  • Additional country-level analysis of the contrast media market

Company profiles

  • Additional three company profiles of players operating in the contrast media market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the contrast media market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3577
Published ON
Feb, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Contrast Media Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback